Financial Performance - The company's operating revenue for Q3 2025 was ¥213,255,740.57, a decrease of 15.72% compared to the same period last year[5] - The net profit attributable to shareholders was -¥2,658,745.89, representing a decline of 120.54% year-on-year[5] - The basic earnings per share were -¥0.0031, down 120.13% from the previous year[5] - Total operating revenue decreased to ¥526,891,688.79 from ¥635,030,298.87, representing a decline of approximately 17.1% year-over-year[30] - Net profit for the period was a loss of ¥31,025,238.07 compared to a profit of ¥28,681,678.30 in the previous period, indicating a substantial decline[31] - Total comprehensive income for the period was -¥38,291,121.64, a significant drop from ¥30,221,773.21 in the prior year[32] - The company experienced a total loss of ¥28,257,351.48 in profit before tax, compared to a profit of ¥31,302,613.93 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,453,688,194.93, a decrease of 2.92% from the end of the previous year[5] - The company's total liabilities as of September 30, 2025, were CNY 1,042,562,022.36, down from CNY 1,054,436,349.33, indicating a reduction of about 1.1%[29] - The company's cash and cash equivalents decreased to CNY 125,287,409.13 from CNY 147,693,180.87, representing a decline of approximately 15.2%[27] - Accounts receivable fell to CNY 27,073,537.72 from CNY 39,169,433.88, a decrease of about 30.9%[27] - Inventory increased to CNY 57,657,756.69 from CNY 50,753,348.55, marking an increase of approximately 13.5%[27] - The company's total equity decreased to CNY 411,126,172.57 from CNY 443,047,294.21, reflecting a decline of about 7.2%[29] Research and Development - Research and development expenses increased by ¥606,000, or 108.60%, compared to the same period last year[9] - Research and development expenses increased significantly to ¥11,646,500.56 from ¥5,583,042.65, marking a rise of approximately 108.5% year-over-year[31] Cash Flow - The company reported a net cash flow from operating activities of -¥10,146,191.88, a decrease of 123.56% year-to-date[5] - The net cash flow from operating activities was negative at -¥10,146,191.88, a decrease from a positive cash flow of ¥43,066,291.87 in the prior year[34] - Cash and cash equivalents at the end of the period stood at ¥110,286,409.13, down from ¥152,382,007.24, reflecting a decrease of approximately 27.6%[34] Legal and Regulatory Issues - The company has disclosed multiple legal proceedings and updates related to the Jin Haitang case, with various court documents filed from 2020 to 2024[15] - The company has reported that it is in communication with the executing party and the Shanghai Financial Court regarding the Jin Haitang asset management case[16] - The company has faced asset freezes due to disputes with Zhejiang Zheshang Asset Management Co., Ltd. and Wenzhou Bank Co., Ltd.[21] - The company has not yet fulfilled its repayment obligations to Zhejiang Zheshang Asset Management Co., Ltd. and is exploring solutions to address its debt issues[21] - The company has disclosed that it has received a debt transfer notification from Zhejiang Zheshang Asset Management Co., Ltd. to Zhejiang Zheba Xianv Lake Enterprise Management Partnership[19] - The company has reported on the freezing of bank accounts and assets of its subsidiaries, with updates provided on various dates in 2023[18] Shareholder and Equity Changes - The total equity attributable to shareholders was ¥364,359,479.58, down 8.46% from the end of the previous year[5] - The number of ordinary shareholders at the end of the reporting period was 46,198[12] - The first major shareholder, 汇垠日丰, has become the sole trustee of a specific asset management plan, indicating a shift in control dynamics[23] - The company is actively preparing a detailed equity change report following recent court rulings affecting its control structure[24] - The company is actively seeking to negotiate with creditors regarding debt relief, extension, installment repayment, and financing replacement options[21] Investor Advisory - The company reminds investors to be aware of investment risks and to invest rationally[17] - Investors are advised to remain cautious and rational in their investment decisions due to ongoing uncertainties surrounding the company's control and financial performance[25]

Core Points - The company held its first extraordinary general meeting of shareholders in 2025, which was conducted legally and effectively [4][5][25] - The meeting involved a combination of on-site and online voting, with a total of 255 shareholders participating, representing 205,608,100 shares, or 24.4772% of the total voting shares [5][6][7] Meeting Details - The meeting took place on October 16, 2025, at 14:45 in Beijing [4] - The meeting was convened by the board of directors and chaired by the company's chairwoman, Ms. Lu Lu [4][9] Voting Participation - A total of 255 shareholders participated, with 3 attending in person and 252 voting online [5][6][7] - Among the participating shareholders, 251 were small investors, representing 5,575,100 shares, or 0.6637% of the total voting shares [8] Resolutions and Voting Results - The meeting approved several resolutions, including amendments to the company's articles of association, with 99.6450% of votes in favor [10][11] - Other resolutions, such as the rules for shareholder meetings and board meetings, also received overwhelming support, with approval rates exceeding 99% [12][14][19][21] Legal Compliance - The legal opinions provided by the law firm confirmed that the meeting's procedures complied with Chinese laws and regulations, ensuring the legitimacy of the voting process and results [25][26]

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于皓宸医疗科技股份有限公司 2025年第一次临时股东大会的法律意见书 致：皓宸医疗科技股份有限公司 北京市竞天公诚律师事务所（以下简称"本所"）接受皓宸医疗科技股份有 限公司（以下简称"公司"）的委托，指派本所律师列席公司于 2025 年 10 月 16 日下午 14:45 在北京市朝阳区光华路 5 号院世纪财富中心东亚银行大厦 18 层 1810 室召开的公司 2025 年第一次临时股东大会（以下简称"本次股东大会"）， 并依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会 规则》等中国现行法律、法规和其他规范性文件（以下简称"中国法律法规"） 及《皓宸医疗科技股份有限公司章程》（以下简称"《公司章程》"）的规定， 就本次股东大会的召集和召开程序、出席会议人员资格、召集人资格、会议表决 程序和表决结果等事宜（以下简称"程序事宜"）出具本法律意见书。 为出具本法律意见书，本所律师审查了公司 ...

证券代码:002622 证券简称：皓宸医疗 公告编号：2025-026 皓宸医疗科技股份有限公司 1．本次股东大会无增加、变更、否决提案的情况。 2．本次股东大会不涉及变更前次股东大会决议。 3．本次股东大会采取现场投票与网络投票相结合的表决方式。 一、会议召开和出席情况 1、会议召开情况 （1）会议时间：2025 年 10 月 16 日（星期四）下午 14 点 45 分 （2）会议地点：北京市朝阳区光华路 5 号院世纪财富中心东亚银行大厦 18 层 1810 室 （3）会议召开方式：采取现场投票和网络投票相结合的方式 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （4）会议召集人：皓宸医疗科技股份有限公司董事会 （5）会议主持人：公司董事长陆璐女士 本次大会的召开符合《公司法》和《公司章程》的有关规定，会议召集、召 开程序、表决程序以及表决结果均合法、有效。 2、会议出席情况 通过现场和网络投票的股东 255 人，代表股份 205,608,100 股，占公司有表 决权股份总数的 24.4772％。 （1） ...

Core Points - The Shanghai Composite Index is at 3906.88 points, above the six-month moving average, with a gain of 0.45% [1] - A total trading volume of A-shares reached 1,197.71 billion yuan today [1] - 158 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The stocks with the highest deviation rates from the six-month moving average include: - Aienju (11.21% deviation, latest price 21.46 yuan) [1] - Huifeng Diamond (8.50% deviation, latest price 31.92 yuan) [1] - Jiuan Medical (4.78% deviation, latest price 40.21 yuan) [1] - Other stocks that have just crossed the six-month moving average include: - Ningbo Energy, China National Heavy Duty Truck Group, and Tongda Shares [1] Trading Data - The trading data for stocks that broke the six-month moving average on October 14 includes: - Aienju: 13.85% increase, 18.54% turnover rate [1] - Huifeng Diamond: 15.53% increase, 14.22% turnover rate [1] - Jiuan Medical: 5.29% increase, 2.42% turnover rate [1] - Additional stocks with notable performance include: - Chutianlong (4.88% increase) and Daqian Ecology (5.04% increase) [1]

Core Viewpoint - The company is planning to revise its internal regulations and amend its articles of association to enhance corporate governance and compliance with legal requirements [2][26][29]. Group 1: Company Governance Changes - The company will no longer have a supervisory board, with its functions being transferred to the audit committee of the board of directors [26][29]. - Amendments to the articles of association and internal regulations are aimed at improving operational standards and governance [2][26][29]. Group 2: Shareholder Meeting Details - The company will hold its first extraordinary general meeting of 2025 on October 16, 2025, with both on-site and online voting options available [6][10][41]. - The record date for shareholders to attend the meeting is set for October 10, 2025 [8][10]. - Shareholders can register for the meeting through various methods, including in-person and electronic means [11][13][14]. Group 3: Voting Procedures - Voting will be conducted through the Shenzhen Stock Exchange trading system and an internet voting platform, with specific time slots designated for each [18][20]. - The voting process will require shareholders to choose between on-site and online voting, with only one method allowed per shareholder [7][10][20]. Group 4: Internal Regulation Revisions - The company has proposed revisions to several internal regulations, including rules for shareholder meetings, board meetings, and independent director systems, all of which have been approved by the board [29][30][41]. - The revised internal regulations will be submitted for approval at the upcoming extraordinary general meeting [2][41].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002622 证券简称：皓宸医疗 公告编号：2025-024 皓宸医疗科技股份有限公司 关于修订《公司章程》及公司部分内部制度的公告 本公司董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 ■ （一）将"股东大会"调整为"股东会"； （二）删除监事会、监事相关规定，由董事会审计委员会行使《公司法》规定的监事会职权； （三）新增"控股股东和实际控制人"章节； （四）新增"独立董事"章节； （五）新增"董事会专门委员会"章节； （六）将股东会股东提案权所要求的持股比例由3%降至1%。 一、关于《公司章程》修订情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章程指引》《关于新〈公司法〉 配套制度规则实施相关过渡期安排》等法律法规及规范性文件的规定，结合公司实际情况，公司拟不再 设置监事会，监事会的职权由董事会审计委员会行使，同时，公司《监事会议事规则》相应废止，公司 各项规章制度中涉及监事会、监事的规定不再适用。 本次事项尚需提交公司股东大会审议，同时提请股东大会授权公司经营管理层办理工商变更登 ...

每经头条（nbdtoutiao）——重磅解读！中国将不寻求WTO新的特殊和差别待遇，意味着什么？ （记者 王晓波） 截至发稿，皓宸医疗市值为27亿元。 每经AI快讯，皓宸医疗（SZ 002622，收盘价：3.21元）9月29日晚间发布公告称，公司第五届第二十五 次董事会临时会议于2025年9月28日以现场结合通讯表决的方式召开。会议审议了《关于修订 <公司章 程> 的议案》等文件。 2025年1至6月份，皓宸医疗的营业收入构成为：医疗口腔行业占比91.98%，开关占比7.69%，租赁业务 行业占比0.33%。 ...

皓宸医疗 信息披露事务管理制度 皓宸医疗科技股份有限公司 信息披露事务管理制度 第一章 总 则 第一条 为规范和加强皓宸医疗科技股份有限公司（以下简称"公司"）信息 披露事务管理，提高信息披露管理水平和质量，切实维护公司和投资者的合法权 益，依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、中国证监会《上市公司信息披露管理办法》、 《深圳证券交易所股票上市规则》（以下简称"《上市规则》"）等法律、法规、规 章的有关规定，制定本制度。 第二章 公司信息披露的基本原则 第二条 本制度所称信息披露是指达到证券监管部门关于上市公司信息披露 的标准要求，根据相关的法律、法规、部门规章及证券监管部门的规范性文件， 将可能对公司股票及衍生品种价格产生较大影响、而投资者未得知的重大事件信 息，在规定时间内，通过规定的媒体，以规定的方式向社会公众公布，向证券监 管部门备案，主要包括但不限于： （一）公司依法公开对外发布的定期报告； （二）公司依法持续公开对外发布的临时报告（包括但不限于股东会决议公 告、董事会决议公告、交易公告和其他重大事项公告；以及深圳证券交易所认为 ...

皓宸医疗 重大信息内部保密制度 第二条 董事会是公司重大信息内部保密工作的管理机构。 皓宸医疗科技股份有限公司 重大信息内部保密制度 第一章 总则 第一条 为规范皓宸医疗科技股份有限公司（以下简称"公司"）的重大信息 内部保密工作，确保信息披露的公平性，保护股东和其他利益相关者的合法权益， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）以及《上市公司信息披露管理办法》、《深圳证券交 易所股票上市规则》（以下简称"《股票上市规则》"）等有关法律、法规、规章以 及《皓宸医疗科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 制定本制度。 皓宸医疗 重大信息内部保密制度 第三条 董事会秘书为公司重大信息内部保密工作负责人。证券部具体负责 公司重大信息内部保密工作的监管及信息披露工作。 第四条 证券部统一负责证券监管机构、深圳证券交易所（以下简称"交易 所"）、证券公司、律师事务所、会计师事务所、资产评估机构等中介机构及新闻 媒体、股东的接待、咨询（质询）、服务工作。 第五条 证券部是公司唯一的信息披露机构。未经董事会或董事会秘书同意， 公司任 ...